International Online Virology Congress

Marie-Thérèse Giudici-Orticoni is director of the Laboratory of Bioenergetics and Protein Engineering, director of the Mediterranean Institute of Microbiology (350 people), director of the Institute of Microbiology, Bioenergy and Biotechnology of Aix-Marseille University (10 laboratories, 14 platforms). Her group has characterized the main metabolic chains of micro-organisms, and now studying their dynamics and interactions under different conditions. She has initiated an innovative axis of ecological engineering, which consists in the microbial study of bacterial consortia involved in bioH2 production. The objective is to establish the parameters governing the metabolic networks in view of biotechnological applications. She is author of 98 publications in refereed journals, scientific coordinator for national and international programs

Ahmed G. Hegazi Prof. of Microbiology & Immunology National Research Center Egypt. He is having Work experience in African Federation of Apiculture Associations (AFAA), 2001- up till now, And also Journal of Bee keeping in Turkey (MELLIFERA), 2000 – up till now. His Awards are Excellent Medal of the First Class, 1995 and also he received the Senior Scientist Prize of National Research Center, 1996.

Microbiology ,Immunology

Professor of Animal and Fish Production, Faculty of Agriculture

Rumen Microbiology

Zhiheng Pei is an Associate Professor in the Department of Pathology at New York University School of Medicine and serves as an Attending Pathologist in the Department of Veterans Affairs New York Harbor Healthcare System, USA. He has broad interests in the etiology and pathogenesis of cancers and chronic diseases. In the past several years, he has been evaluating and pioneering a new concept – microecological disease, in several NIH-sponsored projects involving cancers in the mouth, esophagus, and stomach as well as disease in tonsils. His laboratory defined the esophageal microbiome and demonstrated its association with esophageal adenocarcinoma in one of the Human Microbiome Demonstration Projects sponsored by NIH Roadmap Initiative. His team also discovered the link of periodontal pathogens to oral cavity squamous cell carcinoma. Clinically, he is interested in the diagnosis of diseases due to uncultivable microbial agents in fixed tissue specimens, using molecular techniques.

Clinically, he is interested in the diagnosis of diseases due to uncultivable microbial agents in fixed tissue specimens, using molecular techniques.

Olga V.Kamzolkina is a russian mycologist, professor in the Mycology and Algology Department at Biology faculty of the Lomonosov Moscow State University. Kamzolkina OV founded a cyto-physiologists school for students and PhD students. Olga V. Kamzolkina is author of over 100 publications, several patents and books in the fields of cell biology, fungal cytology and physiology as well as fungal antimicrobial activity and ligth & electron microscopy. She is the member of the European Mycological Association and Obshchestvo Biotekhnologov Rossii Im. Yu.A. Ovchinnikova. She is currently studying fungal endocytosis, mithochondrial organization and functions in mycelial fungi from the different ecological niches. Lecture and laboratory course for bachelors and masters: fungal cell biology, physiology of fungi.

She is currently studying fungal endocytosis, mithochondrial organization and functions in mycelial fungi from the different ecological niches.

Tinatin Doolotkeldieva is a Head and Professor of Plant Protection Department of Agriculture Faculty at Kyrgyz-Turkish Manas University, Kyrgyzstan. She has expertise in Soil Microbiology, Bioremediation of Environment Pollution, Plant-Microbe interactions, Agricultural Biotechnology using molecular tools and management of plant health by using biocontrol agents. She has published more than 220 papers in reputed journals. She is a member of American Association for Microbiology, Molecular Plant- Microbe Interaction Society, British Plant Pathology Society, and Society for Invertebrate Pathology, ‘Global Avalon network “on organic agriculture and others.

She has expertise in Soil Microbiology, Bioremediation of Environment Pollution, Plant-Microbe interactions, Agricultural Biotechnology using molecular tools and management of plant health by using biocontrol agents.

Giulio Filippo Tarro has graduated from Medicine School, Naples University (1962). He was a Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. He was an Oncological Virology Professor, Naples University (1972-1985). Since 2007, he was the Chairman of Committee of Biotechnologies, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization Lifetime Achievement Award (2010). He is the President Foundation de Beaumont Bonelli for Cancer Research

Murine Virology,Antiviral Chemotherapy, Effects of inhibitors on viraI replication, Studies on the role of herpesviruses in cancer, Tumor immunology,Pathology of AIDS

Min-Hua Luo, M.D. & Ph.D., professor at Wuhan Institute of Virology, State Key Laboratory of Virology and CAS Center for Excellence in Brain Science and Intelligence Technology (CEBSIT); affiliate assistant professor, University of Idaho. Dr. Luo received her BSc in Clinical Medicine in 1988; MSc in Microbiology in 1995 from Hunan Medical University; Ph.D. in Infectious Diseases in 1999, collaborate with Innsbruck University, Austria; Postdoct training in Shriver Center, Harvard Medical School in 2002; Research Scientist at Dept. MMBB, University of Idaho in 2004; Assistant professor at Dept. MMBB, University of Idaho in 2008; professor at Wuhan Institute of Virology, CAS in 2009; professor at CAS Center for Excellence in Brain Science and Intelligence Technology (CEBSIT) in 2014. Her research has focused on NEUROVIROLOGY and supported by funding resources of NSFC, NIH. "Hundred Talents" program from CAS, and "973" program from MOST.

Congenital HCMV Infection and Fetal Brain Development Disorders.

Dr. Bukrinsky obtained medical degree (M.D.) from the 2nd Moscow State Medical Institute in Moscow, Russia, and a doctorate (Ph.D.) in Molecular Biology from the Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. Currently Dr. Bukrinsky is Professor of Microbiology, Immunology and Tropical Medicine at the George Washington University School of Medicine and Health Sciences. He is a Fellow of the American Heart Association, the Editor-in-Chief of the Open AIDS Journal, and member of the Editorial Advisory Board of several biomedical journals. Dr. Bukrinsky’s research interests are in molecular mechanisms governing HIV replication and pathogenesis. His latest research focuses on changes in cholesterol metabolism induced by HIV and its protein Nef. Dr. Bukrinsky has published over 150 scientific papers, reviews and book chapters and is an inventor on 12 issued U.S patents.

HIV lifecycle, the mechanisms of HIV replication in host cells and the mechanisms of HIV pathogenesis and its effects on different tissues and organs, HIV-antigen-based diagnostic system

Zajac V has completed his PhD in 1982 from the Cancer Research Institute of Slovak Academy of Sciences in Bratislava (Slovakia), where he worked as the Head of Department of Cancer Genetics from 1996 to 2010. He joined the Medical Faculty of the Comenius University as an Associate Professor of Genetics in 2007. He has published 69 papers mostly in reputed journals and he was editor of the book “Bacteria, viruses and parasites in AIDS process” (InTech, 2011).

Vaccines, Immunology, Microbiology

Dr. Marco Ciotti has received his Medicine Degree in “La Sapienza” University of Rome in 1989; an Oncology degree at the University of Rome “Tor Vergata” in 1994, and a degree in Microbiology and Virology in 2001 in the same University. Since 2002, he works as Microbiologist at the University Hospital Tor Vergata, Rome, Italy. His main field of interests are HPV and cervical carcinogenesis, pathogenetic role of human polyomaviruses in immunocompromised patients, and diagnosis and molecular characterization of hepatitis viruses. He is serving as an editorial member of several reputed journals. He authored several research articles, one book, and chapters of books. He is a member of the Italian Society of Microbiology.

Human polyomaviruses,Hepatitis viruses

Prof Walsh’s group work on plant - virus interactions. He has published in excess of 270 research articles, 55 of which are in refereed scientific journals. He is particularly interested in natural plant resistance to viruses and has strong links with those who use the outcomes of his research and are involved in delivering them to the end users. The major thrust of this research is to identify, understand and exploit broad-spectrum, durable resistance to plant viruses. His group has had a number of major international (Spain, Germany, Holland, Sweden, Canada, China, Japan) and industry collaborations that have resulted in joint grants and joint publications. He is a past president of the International Working Group on Legume and Vegetable Viruses.

Plant virus interactions

Dr. Glorioso began his career as a professor in the Microbiology and Immunology and Laboratory Animal Medicine at the University of Michigan School of Medicine in 1976 and later in 1989, he moved to the University of Pittsburgh School of Medicine as the W.S McEllroy Professor and Chair of the Department of Microbiology and Molecular Genetics. He has established a 40-year history of research related to the basic biology and genetics of herpes simplex virus. His contributions to the field include defining antiviral immune responses to infection, the genetics of viral pathogenesis and latency, and mechanisms of viral infection. He has been a pioneer in the design and application of HSV gene vectors for the treatment of nervous system diseases such as peripheral neuropathies, chronic pain, and brain tumors. Dr. Glorioso’s most recent research has focused on (i) the design and application of HSV gene vectors for exploring the molecular events that occur in sensory afferents that are involved in the transition from acute to chronic pain, and he has been applied knowledge gained to the treatment of cancer-related pain in phase I clinical trials and (ii) the development of fully retargeted oncolytic HSV vectors for tumor-selective infection and microRNA controlled replication in human glioblastomas. This research has been applied to the treatment of syngeneic and xenograft models of human brain tumors. His research has launched two Biotech companies, Oncorus Inc. in Cambridge, MA and Coda Biotherapeutics Inc in San Francisco, CA. Oncorus utilizes oncolytic HSV vectors for the treatment of solid tumors by tumor lysis combined with immunomodulatory arming genes for induction of anti-tumor immunity. Coda Bio is a neuromodulation company that employs chemical genetics to silence painful conditions such as trigeminal and post-herpetic neuralgia and for treatment of neurogenic bladder, tremor and epilepsy.

HSV, viral infections

Dr. Ilya B. TSYRLOV graduated from Novosibirsk University Medical School (M.D. diploma with distinction). Received a Ph.D. in Biochemistry, and a D.Sci. (higher doctorate degree) in Biochemistry. Hold progressively responsible positions in academia, industry and govermental settings: Group Leader (1973-79), Head of Laboratory (1979-87), then Department of Xenobiochemistry (1987-92) at Russian National Academy of Science. In the United States: Senior Scientist at National Cancer Institute, NIH (1991-95); professor (1995-2010), then visiting associate professor (2010- ) at Mount Sinai School of Medicine, Department of Medicine. In 2005, founded and since then has served as Chief Scientific Officer at XENOTOX, Inc., an innovation science consulting non-profit company. Has forty years of experience and a world-class reputation in studies on molecular mechanisms of monooxygenases induction and drug metabolism; site-directed structure modification of analgesics, synthetic opioids, and antimalarials; research decoding mechanisms underlying human virus genome transcriptional activation by the most potent xenobiotic, dioxin. Established and developed Xenobiotical Virology, an interdisciplinary biomedical discipline dealing with mechanisms of potent xenobiotics’ effect on DRE-containing genes of human viruses, and transcription factors and cytokines linked to inflammation and malignancy pathways. Author of 4 monographs and 230+ peer reviewed publications.

Xenobiotical Virology

Doctor of Biological Sciences, Professor In 1969 he graduated from Yerevan State University with major in biochemistry. The most important outcomes of the scientific results: He has developed and proposed methods for diagnosis and differential diagnosis of diseases, for hemoblastosis prognosis, diagnosis and therapy methods. "Petamcin-A" is a medicine created by him which is introduced in practical medicine. Professor P. A. Ghazaryan has published 441 scientific papers and two textbooks (Moscow), two monographs (2012, Germany). He holds a number of patents. P.A. Ghazaryan headed 26 candidate and supervised 4 doctoral theses. Since 1975 he is a member of Specialized Council 042 on Biochemistry and Molecular Biology, and since 2005 he is deputy chief editor of the scientific journal "Blood". Since 2010 he is editor-in-response of "Pharma” 'scientific-practical journal. In 2007 he became a member of the American Association of Chemists. Then he was elected a full member (academician) of the Academies of Natural Sciences of RF (2008), of the Medical and Technical Sciences of RF (2009), the European Natural Sciences (Germany, 2010). Since 2012 he is the reviewer of the American Journal of Biochemistry, the Clinical Medicine and Diagnostics, and the American Journal of Medicine and Medical Sciences.

Molecular biology

Piotr Staszczuk was born on May 17, 1949 in Poland. He studied chemistry at the Maria Curie-Skłodowska University, graduated in 1972, received Ph.D in 1980 and Sc.D in 1987. He received the professor position at the Maria Curie-Skłodowska University in 1995 and the full professor title in 2001. In 1990-1992 he was the vice-Dean for education of the Faculty of Chemistry and in 1991-1992 he was the supervisor (protector) of the Department of Stereo- and Spectrochemistry. In 1989 he organized his research Thermal Analysis Group and he was the head of organized Department of Physicochemistry of Solid Surfaces in 1998-2006. He is the head of organized in 2010 of the Department (Cathedral) of Bionanomaterials, Institute of Biotechnology, the John Paul II Catholic University (KUL) of Lublin. In February 21, 2013 he was elected as director of Institute of Biotechnology, Faculty of Biotechnology and Natural Sciences of KUL.

Biotechnology

Since 2005 - a CSO at XENOTOX, Inc. Have a medical background (M.D., 1970), Ph.D. in Biochemistry (1973), D.Sc. in Molecular Toxicology (1983). Hold progressively responsible positions: Group Leader (74-79), Head of the Laboratory (1979-87), Department Chair (1987-91), all at Russian Academy of Science. In the US: a Senior Scientist at NCI, NIH (1991-95), Professor (since 2010 - visiting) at Mount Sinai School of Medicine (1995-to date). Author of 5 monographs and 250+ peer reviewed publications. By using enzyme-kinetic and inhibitory analyses, pioneered in revealing TCDD-induced CYP1B1 (FEBS Letters, 1987). Invented the recombinant and TCDD-induced microsomal and isolated monooxygenase isoforms CYP1A1 and CYP1A2, to study regulatory effects of bioflavonoids on procarcinogens metabolism in humans (BBA, 1994). Since the discovery of trans-activation effect of TCDD on HIV-1 (BBRC, 1991), have established Xenobiotical Virology, a biomedical discipline dealing with mechanisms of dioxin effects on DRE-containing genes of human viruses, transcription factors and cytokines linked to inflammation and malignancy pathways.

Viruses

Ronald Moss, M.D. has served as the Chief Executive Officer of Ansun Biopharma, Inc. since October 2012, and before that, served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine development of products in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology

Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity.

Professor Ting-Chao Chou received MS degree in Pharmacology from National Taiwan University College of Medicine; Ph.D. from Yale University, and Postdoctoral Fellowship at Johns Hopkins University School of Medicine. Joined Memorial Sloan-Kettering Cancer Center (MSKCC), became Member 1988-96, and a Professor of Pharmacology at Cornell University Graduate School of Medical Sciences, 1988-2000. He is Honorary Professor at Chinese Academy of Medical Sciences, Beijing and five other universities. He focused in the new drug discovery as the Director of Preclinical Pharmacology Core at MSKCC, where he retired on June1, 2013. His 273 scientific articles have been cited by 15,606 papers (as of 8.31.2014). (Thomson Reuters Web of Science: www.researcherid.com/rid/B-4111-2009). Prof. Chou introduced the “Unified Theory of the Median-Effect Equation of the Mass-Action Law”, and with Prof. Paul Talalay (JHU) in 1984, created the “Combination Index Theorem” for multiple entity dynamics. For one article alone (Chou TC and Talalay P., Adv Enz Regul 22:27-55, 1984), cited by 3,218 articles published in 599 biomedical journals and has become one of four the most broadly cited theoretical articles by journals of all time. Chou's dynamics equations and theory has been extended to illustrate the ancient Chinese philosophy and to advocate Econo-Green Bio-Research. He is Inventor/Co-inventor of 36 U.S. Patents, on Editorial Board of five international scientific journals, and is the founder of PD Science, LLC.

Virology

Dr. Olga S. Latinovic is an assistant professor working at the Institute of Human Virology (IHV) led by Robert C. Gallo, M.D. at the University of Maryland, School of Medicine in Baltimore, MD, USA. Her research focus is on developing novel antiviral therapy strategies using various HIV entry inhibitors, with a particular focus in understanding antiviral synergistic activity and its mechanism between CCR5 antagonists and CCR5 antibodies extensively collaborating with Dr. Robert R. Redfield, MD. Dr. Latinovic wrote the book Micromechanics and Structure of Soft and Biological Materials, and published by Verlag Dr. Muller in 2010, and co-authored the book Handbook of Photonics for Biomedical Engineering published by Springer-Verlag in 2016. Dr. Latinovic lectures Virus Entry course for the grad students at the Department of Microbiology and Immunology at the University of Maryland, School of Medicine.

Viruses

Associate Professor Shubhada Bopegamage, MSc., PhD is a Virologist currently heading the Enterovirus Laboratory and the National Reference Center for Identification of Enteroviruses at the Medical Faculty of the Slovak Medical University in Bratislava, Slovakia. Her work is focussed on the pathogenesis and diagnosis of enteroviruses. She received her BSc. Microbiology degree from Pune, India and MSc. Microbiology degree from Mumbai, India. She got her PhD in Biological Sciences from the Academy of Medical Sciences, Moscow, Russia. She is known in the Enterovirus research since 2005 for her work on the in vivo experimental coxsackievirus oral infection of mice. She is involved in research and teaching and has guided several MSc. and PhD students. She has co-ordinated and has lead several national and international projects as a principal or co-investigator.

Enterovirus and coxsackievirus oral infections.

Dr. Nossik Nikolai N. Graduated from Moscow Medical University, physician. PhD (1960), Doctor of Science ( 1988), professor (1990). In 1968 - 1973 the WHO expert in SEARO (India) on national and international projects on virology and epidemiology. Main activity was connected with poliomyelitis in India and afterwords was conducted to enteroviruses in South-East Asia Region (India, Nepal, Burma, Thailand).In 1975 as a visiting scientist was doing the research study on oncornaviruses at the National Institute of oncology ( Fort Detrick). In 1976 and 1978 as visiting scientist was involved in the study on interferons (ISERM program) in Paris, France.Main scientific interests - antiviral and virucidal preparations, interferons , immunomodulators. He is the head of laboratory of virus ontogenesis in Ivanovsky Institute of virology, “N.F. Gamaleya FRCEM», Moscow, Russia. He has published 3 monographies, 6 books chapters and more than 200 papers in scientific journals.

Main scientific interests - antiviral and virucidal preparations, interferons , immunomodulators. He is the head of laboratory of virus ontogenesis in Ivanovsky Institute of virology, “N.F. Gamaleya FRCEM», Moscow, Russia. He has published 3 monographies, 6 books chapters and more than 200 papers in scientific journals

amal El Sawaf is a Professor of Microbiology and Immunology Medical Research Institute, Alexandria University, Egypt. He is a nationally recognized leader in infectious diseases. He was graduated from the Faculty of Medicine, Alexandria University in 1979. He has obtained his PhD in 1993 and his Post Doctor training course in the Laboratory of Infectious Diseases (Cattedra Di Clinica Delle Malattie Infettive) University of Rome, Tor Vergata. He was appointed as the Head of Microbiology Department in 2008 and the Director of the Medical Technology Center in 2010 and finally, the Dean of MRI. His main fields of research activities are in the clinical aspects pathogenesis and therapy of HCV, HIV and HHV-8 infection and epidemiology and molecular characterization of hepatitis viruses in Egypt. He has acted as a Referee for a variety of national and international scientific journals and as a Referee of research projects of the Alexandria University and of the STDF projects. He is a Member of the American Society of Microbiology, The Egyptian Society of Microbiology and Egyptian Society of Immunologists. He is a Project Leader of several research programs on HCV, HHV and TB

HCV, HHV and TB

Dr.Zenab Torky is an Assistant Professor of Microbiology in the department of Microbiology, Faculty of Science, Ain Shams University, in Egypt. She also worked as a Visiting Scientist in the department of Biological Sciences, University of Louisville, USA. Dr.Zenab has also reviewed and edited many papers for the Food Safety Journal, and participated in two projects with members of the Remold laboratory in University of Louisville, to study the nature and conditions of adaptations of vesicular somatitis virus to a cancer cell line, using molecular biology techniques like genome sequencing and phenotypic characterization of recombinant viruses, to design oncolytic viruses that kill cancer cells, and sampling, genotypic and phenotypic characterization of Pseudomonas bacteria species isolated from human homes, and their pets.

Dr.Zenab’s main research interest is finding a way to protect living cells from viral infection, by studying ways to strengthen the immunity of the host by using natural compounds like antivirals, and studying their effect on viral replication

Dr. Hemida received his Ph.D from University of Guelph, 2009. He pursued his PDF training at the the University of British Columbia (James Hogg iCapture Centre). His research area of interest is “One Health Concept” with special emphasis on emerging viruses/host interaction. Currently, studying the molecular evolution and pathogenesis of MERSCoV in the Middle East. He published more than 40 original Research papers on high impacted journals. Meanwhile, he received several Research grants, prestigious honors and scholarship throughout his academic carrier. Currently, he is a reviewer of many granting agencies as well as editorial board member of many international journals

Study of the molecular evolution and pathogenesis of MERSCoV in the Middle East.

C. Yong Kang has completed his PhD from McMaster University in Canada and post-doctoral training at the University of Wisconsin-Madison. He served as a Professor of Virology at the University of Texas Southwestern Medical School, Professor and Chairman at the University of Ottawa Faculty of Medicine, and Dean of Science at the University of Western Ontario. He has published 137 peer reviewed research papers and 151 scientific proceedings and abstracts. He holds nine international biotechnology patents. He received numerous awards including the Ho-Am Prize in Medicine. He is a Life-time Fellow of the Royal Society of Canada Academy of Science. He serves as a reviewer for eight international journals.

His research in molecular virology includes the development of viral-specific antiviral therapeutic agents and efficacious vaccines against various human viral diseases including AIDS, hepatitis and hemorrhagic fever with renal syndrome.

DC Tang is the Founder of VaxDome LLC and Vaxin Inc. He was a pioneer during the development of DNA vaccines, noninvasive skin-patch vaccines, adenovirus-vectored vaccines, and the protective innate-adaptive immunity duo platform technology. He was selected as a Distinguished Overseas Scientist by the South Korea KOFST Brain Pool Program; subsequently joined Chung-Ang University and International Vaccine Institute in Seoul; and was appointed as a Scientist at IVI after the Brain Pool Program Award expired in 2013. He founded VaxDome LLC in Birmingham, Alabama, USA in 2014 and moved the company to Dallas, Texas, USA in 2015.

DNA vaccines, noninvasive skin-patch vaccines, adenovirus-vectored vaccines, and the protective innate-adaptive immunity duo platform technology

Professor Ting-Chao Chou received MS degree in Pharmacology from National Taiwan University College of Medicine; Ph.D. from Yale University, and Postdoctoral Fellowship at Johns Hopkins University School of Medicine. Joined Memorial Sloan-Kettering Cancer Center (MSKCC), became Member 1988-96, and a Professor of Pharmacology at Cornell University Graduate School of Medical Sciences, 1988-2000. He is Honorary Professor at Chinese Academy of Medical Sciences, Beijing and five other universities. He focused in the new drug discovery as the Director of Preclinical Pharmacology Core at MSKCC, where he retired on June1, 2013. His 273 scientific articles have been cited by 15,606 papers (as of 8.31.2014). (Thomson Reuters Web of Science: www.researcherid.com/rid/B-4111-2009). Prof. Chou introduced the “Unified Theory of the Median-Effect Equation of the Mass-Action Law”, and with Prof. Paul Talalay (JHU) in 1984, created the “Combination Index Theorem” for multiple entity dynamics. For one article alone (Chou TC and Talalay P., Adv Enz Regul 22:27-55, 1984), cited by 3,218 articles published in 599 biomedical journals and has become one of four the most broadly cited theoretical articles by journals of all time. Chou's dynamics equations and theory has been extended to illustrate the ancient Chinese philosophy and to advocate Econo-Green Bio-Research. He is Inventor/Co-inventor of 36 U.S. Patents, on Editorial Board of five international scientific journals, and is the founder of PD Science, LLC.

Virology

Ronald Moss, M.D. has served as the Chief Executive Officer of Ansun Biopharma, Inc. since October 2012, and before that, served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine development of products in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology

Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity.

Since 2005 - a CSO at XENOTOX, Inc. Have a medical background (M.D., 1970), Ph.D. in Biochemistry (1973), D.Sc. in Molecular Toxicology (1983). Hold progressively responsible positions: Group Leader (74-79), Head of the Laboratory (1979-87), Department Chair (1987-91), all at Russian Academy of Science. In the US: a Senior Scientist at NCI, NIH (1991-95), Professor (since 2010 - visiting) at Mount Sinai School of Medicine (1995-to date). Author of 5 monographs and 250+ peer reviewed publications. By using enzyme-kinetic and inhibitory analyses, pioneered in revealing TCDD-induced CYP1B1 (FEBS Letters, 1987). Invented the recombinant and TCDD-induced microsomal and isolated monooxygenase isoforms CYP1A1 and CYP1A2, to study regulatory effects of bioflavonoids on procarcinogens metabolism in humans (BBA, 1994). Since the discovery of trans-activation effect of TCDD on HIV-1 (BBRC, 1991), have established Xenobiotical Virology, a biomedical discipline dealing with mechanisms of dioxin effects on DRE-containing genes of human viruses, transcription factors and cytokines linked to inflammation and malignancy pathways.

Viruses

Sita Awasthi has received her Ph.D in Biochemistry from Devi Ahilya University at Indore, India and her postdoctoral training from University of Pennsylvania at Philadelphia. Currently she is a Research Assistant Professor at University of Pennsylvania, Pearlman School of Medicine, Infectious Disease Division. Her research interests are HSV-2 vaccine development against genital herpes disease and HSV-2 HIV-2 co-infections. She has published numerous research articles and serving as an editorial board member of Journals of antivirals and anti retrovirals, Journal of Immunoassay and Immunochemistry.

HIV and Different Viruses

Walter Doerfler has completed Munich Medical School (LMU), Doctor of Medicine thesis in Anatomy and Internships in Munich and Trenton, NJ, USA. He did his Postdoctoral studies in Molecular Genetics at the Max-Planck-Institute for Biochemistry in Munich and in the Department of Biochemistry, Stanford University Medical School.

Genetics and Molecular Virology

Zhanglei has completed her PhD at the age of 30 years from Heping Campus Jilin University. Now she is a associate professor and postgraduate tutor of institute of Special Wild Economic Animals and Plants, Chinese Academy of Agricultural Sciences. Mainly engaged in fur animal disease including molecular epidemiological investigation and diagnosis products research work

Mainly engaged in fur animal disease including molecular epidemiological investigation and diagnosis products research work

Marcin Sieńczyk graduated from the Molecular Biotechnology and Biocatalysis program in 2002 at Wroclaw University of Technology, four years later he obtained his PhD in Medicinal Chemistry. In 2015 he was awarded habilitation (DSc) in Biotechnology. He currently holds the position of assistant professor at Wroclaw University of Technology, Division of Medicinal Chemistry and Microbiology. His research is focused on the development of low molecular weight compounds designed to target proteases involved in the pathogenesis of various diseases including cancer, bacterial and viral infections. Work in his laboratory also generates antibodies to be used in the development of new diagnostic assays for human diseases. He is a co-author of more than 40 papers, 14 patents and more than 25 pending patent applications.

Viruses

Dr.Zenab Torky is an Assistant Professor of Microbiology in the department of Microbiology, Faculty of Science, Ain Shams University, in Egypt. She also worked as a Visiting Scientist in the department of Biological Sciences, University of Louisville, USA. Dr.Zenab has also reviewed and edited many papers for the Food Safety Journal, and participated in two projects with members of the Remold laboratory in University of Louisville, to study the nature and conditions of adaptations of vesicular somatitis virus to a cancer cell line, using molecular biology techniques like genome sequencing and phenotypic characterization of recombinant viruses, to design oncolytic viruses that kill cancer cells, and sampling, genotypic and phenotypic characterization of Pseudomonas bacteria species isolated from human homes, and their pets.

Dr.Zenab’s main research interest is finding a way to protect living cells from viral infection, by studying ways to strengthen the immunity of the host by using natural compounds like antivirals, and studying their effect on viral replication.

Girish J. Kotwal, received his Ph.D. from the Biochemistry department, McMaster University, Canada in 1985. He did his post doctoral work at the National Institutes of Health (NIH) in Bethesda, MD, USA in the Laboratory of Viral Diseases from 1984-1990 and co-discovered the vaccinia virus complement control protein (VCP) along with Dr. Bernard Moss, member of the US National Academy of Science (NAS). During the 90s he established a structural biology program which included overexpression of VCP, a heavily disulphide bonded protein and directed the preclinical program to evaluate the therapeutic potential of VCP. In 2002 he founded Kotwal Bioconsulting, LLC, in 2004 he founded kbiotech pvt. ltd., in South Africa, in 2005 he co-founded InFlaMed Inc. in USA. In 2010 he assisted in founding Icelandic Cardio Pharma (IceCP) in Iceland. He is currently Professor of Biochemistry and Microbiology at UMHS, WI, Adjunct Professor of Medicine, UMass medical school, Worcester, MA and Adjunct Professor of Traditional Chinese Medicine at Henan University, China. He has authored over 100 publications, 97 of which are found on pubmed.

Medical Microbiology, Dental Microbiology and Immunology, Cellular and Molecular Immunology, Intracellular signaling mechanisms in lymphoid cell activation, Cytolytic mechanisms of CTLs and NK cells, Complement pathways & complement regulatory proteins, Immune responses against tumors, Mechanisms of apoptosis in the immune system, transgenic and knockout mice, Modern vaccine design & immunization, HLA & TCR genes in autoimmunity, cellular and molecular mechanisms of autoimmunity, Fundamental Virology, Molecular Virology,

Dominic Targema Abaver has completed his Ph.D.at the age of 40 years from University of Abuja in parasitology; He is chief superintendent of Immigration Nigerian Immigration service, a paramilitary organization in the ministry of interior. He has published number of papers on HIV/AIDS, Immunology and parasitology in reputed journals, such as African Health Science, Pakistani Journal of Medical sciences, African Journal for Physical, Health Education, Recreation and Dance (AJPHERD). He is a member of Nigerian society of parasitology and a fellow, Institute of Cooperate Administration. Currently, D.T. Abaver is a Contract Researcher at Walter Sisulu University, Eastern Cape, South Africa. His research interest include Epidemiology of HIV/AIDS and other Opportunistic Infections; Preventive measures/techniques of HIV/AIDS; gender, age and sexual orientation as determinants for the impact of HIV/AIDS

HIV/Aids

Dr Benani is a responsible of Molecular Biology Laboratory at Pasteur Institute of Morocco this laboratory is a national reference laboratory for Hepatitis C Program (Moroccan ministry of health). He is also the elect-president of Arab Society for Virology and Active member on the Advisory Board, Consultative Meeting on Regional Strategy for Prevention and Control of Viral Hepatitis and Other Epidemics-Prone Blood-Borne Diseases, in 2008 (WHO/EMRO, Cairo, Egypt). He got his master of molecular biology and biotechnology at Université Libre of Bruxelles (ULB, Belgium) and his PhD in molecular microbiology in Fes University (Morocco). He participates in several international and national workshops and congresses. He is also implicated in student’s research for their training, master, and PhD. He published in several journals including journal of medical virology, BMC public health, Virology Journal, He is an active researcher in molecular epidemiology of HBV and HCV in general population and high Risk groups in Morocco. He organized the 1st International Symposium for Virology in Morocco in 2003 (Marrakech, Morocco) and the First PCR Forum and Molecular Typing at Pasteur Institute of Morocco

Molecular epidemiology of HBV and HCV